Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy

BACKGROUND: Adoptive cell therapy with T cells genetically engineered to express a chimeric antigen receptor (CAR-T) or tumor-infiltrating T lymphocytes (TIL) demonstrates impressive clinical results in patients with cancer. Lymphodepleting preconditioning prior to cell infusion is an integral part...

Descripción completa

Detalles Bibliográficos
Autores principales: Nissani, Abraham, Lev-Ari, Shaked, Meirson, Tomer, Jacoby, Elad, Asher, Nethanel, Ben-Betzalel, Guy, Itzhaki, Orit, Shapira-Frommer, Ronnie, Schachter, Jacob, Markel, Gal, Besser, Michal J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127974/
https://www.ncbi.nlm.nih.gov/pubmed/33990415
http://dx.doi.org/10.1136/jitc-2020-001743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127974/
https://www.ncbi.nlm.nih.gov/pubmed/33990415
http://dx.doi.org/10.1136/jitc-2020-001743

Ejemplares similares